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ABSTRACT
Objective To determine the relation between
concentrations of prostate specific antigen at age 60 and
subsequent diagnosis of clinically relevant prostate
cancer in an unscreened population to evaluate whether
screeningforprostatecancerandchemopreventioncould
be stratified by risk.
Design Case-control study with 1:3 matching nested
within a highly representative population based cohort
study.
Setting General population of Sweden taking part in the
Malmo Preventive Project. Cancer registry at the National
Board of Health and Welfare.
Participants 1167 men aged 60 who provided blood
samples in 1981 and were followed up to age 85.
Main outcome measures Metastasis or death from
prostate cancer.
Results The rate of screening during the course of the
study was low. There were 43 cases of metastasis and 35
deaths from prostate cancer. Concentration of prostate
specific antigen at age 60 was associated with prostate
cancer metastasis (area under the curve 0.86, 95%
confidenceinterval0.79to0.92;P<0.001)anddeathfrom
prostate cancer (0.90, 0.84to 0.96; P<0.001).The greater
the number for the area under the curve (values from 0 to
1) the better the test. Although only a minority of the men
with concentrations in the top quarter (>2 ng/ml) develop
fatal prostate cancer, 90% (78% to 100%) of deaths from
prostate cancer occurred in these men. Conversely, men
aged 60 with concentrations at the median or lower (≤1
ng/ml) were unlikely to have clinically relevant prostate
cancer(0.5%riskofmetastasisbyage85and0.2%riskof
death from prostate cancer).
Conclusions The concentration of prostate specific
antigen at age 60 predicts lifetime risk of metastasis and
death from prostate cancer. Though men aged 60 with
concentrations below the median (≤1 ng/ml) might
harbour prostate cancer, it is unlikely to become life
threatening. Such men could be exempted from further
screening,whichshouldinsteadfocusonmenwithhigher
concentrations.
INTRODUCTION
Testing for prostate specific antigen is widely used for
theearlydetectionofprostatecancer.Evenbeforeran-
domisedevidenceastotheeffectsofscreeningonmor-
talitybecameavailable,
12abouthalfofageappropriate
men in the United States presented for regular tests.
3
The operating characteristics of the prostate specific
antigen test have been determined by comparing
concentrations with the result of prostate biopsy.
4-6 A
notablefeatureofsuchstudiesisthatmenwithconcen-
trationsbelowcommonlyusedbiopsythresholds,such
as 4 ng/ml, have a substantial risk of cancer detectable
at biopsy.
7 Yet it has been established from autopsy
studiesthatmanymendyingofcausesotherthanpros-
tate cancer none the less harbour prostate tumours. A
typical estimate is that close to 40% of 70 year old men
havedetectablecancerintheprostateatautopsy.
8This
figure is reflected in the widely recognised problem of
overdiagnosis,
910with the European randomised trial
suggesting that 48 men with screen detected cancer
need to be treated for one death from prostate cancer
to be avoided at nine years.
2
Accordingly, the key question is not whether a man
has prostate cancer but whether that cancer is likely to
cause symptomsor shorten his life.In 1981-2, a highly
representative cohort of 60 year old Swedish men pro-
vided blood samples for cardiovascular studies as part
of the Malmo Preventive Project.
1112 We have been
able to match these samples to cancer registries
updated on 31 December 2006, when participants
had either died or reached their 85th birthday. The
rate of prostate specific antigen screening in Sweden
during this time was low,
13 and men in this cohort
would have been too old to be eligible for screening
bythetimethescreeningtestbecameavailableinSwe-
den in the 1990s. As such, the study provides a natural
experimenttodeterminetheassociationbetweenpros-
tate specific antigen concentrations, taken at an age
typical for a man undergoing screening, and lifetime
riskofclinicallydetectedprostatecancer,prostatecan-
cer metastasis, and death from prostate cancer.
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Study participants
The Malmo Preventive Project has been previously
described.
1112 The cohort reported here includes
1167menbornin1921,constituting71%oftheeligible
population, who gave blood and completed medical
history and lifestyle questionnaires in 1981-2. Records
of participants were linked to the cancer registry at the
National Board of Health and Welfare in Sweden to
identify men diagnosed with prostate cancer up to 31
December 2006. This registry has been shown to be
highly accurate.
14 We excluded five men diagnosed
with prostate cancer before the date of their baseline
blood sample. Medical charts were available for 101
of 126 men (80%) with a diagnosis of prostate cancer,
including 73 of 88 men (83%) who subsequently died.
One urologist (DU), blinded to baseline prostate spe-
cific antigen data, reviewed charts, which were also
independently reviewed for cause of death (by TB).
Whenmedicalchartswerenotavailable,dataonmeta-
stasis were taken from National Cancer Registry data
on stage at diagnosis (14 patients, six with metastasis);
cause of death was obtained from the Causes of Death
Registry at the National Board of Health and Welfare
in Sweden (n=15, six deaths from prostate cancer).
Weusedanestedcase-controldesigntoanalysedata
from the cohort.Separate matches were conducted for
each of the three study events: clinically diagnosed
prostate cancer, prostate cancer metastasis, and death
from prostate cancer. A metastasis event included
metastases documented at the time of diagnosis of
prostatecanceraswellasthosemetastasesdocumented
subsequently. Men who died from prostate cancer
without previous clinical documentation of metastasis
weredefinedashavingbeendiagnosedwithmetastasis
at the date of death. For each end point, we selected
three controls at random from the group of men alive
and event-free at the time of the event in the affected
patient (the case) during follow-up. Controls were
matched on date of birth and date of baseline blood
sample, with a window of three months. Using this
algorithm, we successfully matched three controls to
each case for all of the study end points.
Laboratory methods
Total prostate specific antigen was assayed in anti-
coagulated blood plasma stored at −20°C for up to
27years.Wehaveshownthatprostatespecificantigen
is not significantly labile when stored under these
conditions.
15 Levels of total prostate specific antigen
(plus free prostate specific antigen and kallikrein
related peptidase 2 (hK2)) were determined as pre-
viously reported
1617 and conducted in accordance
withWorldHealthOrganizationcalibrationstandards
at Lund University.
Statistical methods
Weusedconditionallogisticregressiontotesttheasso-
ciation between prostate specific antigen concentra-
tions and study end points. The area under the
receiver operating characteristic curve was calculated
directly from the concentrations, with confidence
intervals obtained by the method of Delong et al.
18
The area under the curve is a simple quantitative sum-
mary value of whether the continuous measure (in this
caseprostatespecificantigen)isagooddiagnostictool.
Values can lie between 0.5 and 1, with higher values
showing greater diagnostic power. All statistical ana-
lyses were conducted with Stata 10.1 (StataCorp LP,
College Station, TX).
To estimate the risk of the prostate cancer outcomes
for a given concentration, we used locally weighted
scatterplot smoothing (LOWESS)
19 to allow for a
non-linear relation between prostate specific antigen
and outcome. To obtain population based estimates
ofrisk,wefirstimputedconcentrationsforparticipants
without measured prostate specific antigen—623 men
without a diagnosis of prostate cancer who were not
selected as controls—by randomly sampling concen-
trations with replacement from cancer-free controls.
We then used LOWESS to estimate risk; the imputa-
tion and estimation was repeated 200 times, with the
Table 1 |Characteristics of entire study cohort (n=1162) at 31
December 2006. Figures are numbers (percentages) unless
stated otherwise
Data
Alive at age 85:
Without prostate cancer 360 (31)
With non-metastatic prostate cancer 38 (3)
With metastatic prostate cancer 0 (0)
Died from other causes:
Without prostate cancer 668 (57)
With non-metastatic prostate cancer 45 (4)
With metastatic prostate cancer 8 (1)
Died from prostate cancer 35 (3)
Emigrated 8 (1)
Median (IQR) PSA at age 60 (ng/ml)* 1.06 (0.65-1.92)
IQR=interquartile range; PSA=prostate specific antigen.
*Imputed to whole population from case-control data.
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Fig 1 | Lifetime risk of clinically diagnosed prostate cancer or
prostate cancer metastasis. Shaded region represents
population based distribution of prostate specific antigen.
Curves for risk of death from prostate cancer nearly overlap
with curves for prostate cancer metastasis and are not shown
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Centile based confidence intervals for both the risk
curveandtheLorenzcurve
20wereobtainedwithboot-
strap methods.
RESULTS
Table 1showscharacteristicsoftheentirecohortat31
December 2006. A total of 126 men were diagnosed
withprostatecancer,ofwhom43eitherhadmetastatic
disease at diagnosis (n=13), subsequently developed
metastases (n=18), or died from prostate cancer with-
out clinical documentation of metastases (n=12).
Thirty five men died from prostate cancer. We
excluded one case (a man who died from prostate can-
cer) from the analysis because blood samples were
insufficient to measure prostate specific antigen. We
also excluded 11 controls (two matched for prostate
cancer, five matched for metastases, and four matched
for death) with insufficient blood samples. Median
times to diagnosis, metastasis, and cancer specific
death were 15.3, 15.7, and 15.9 years, respectively.
The similarity of these estimates is because only a sub-
set of men diagnosed with cancer went on to develop
metastases and these tended to be diagnosed earlier.
The imputed median prostate specific antigen concen-
tration for the entire cohort was 1.06 ng/ml (inter-
quartile range 0.65-1.92), similar to that reported for
US men.
21
Table 2 gives details of the diagnosis in the 126
affected men. Most commonly, prostate cancer was
detected during investigation for urinary symptoms
(79%). No man had cancer detected by screening.
Curativetreatmentwasrare,withonlyonemanunder-
going radical prostatectomy. Bone scans were not rou-
tine for much of the period of the study, and many
patients are therefore not classified for metastasis at
diagnosis.
Prostate specific antigen at age 60 was associated
with risk of prostate cancer diagnosed clinically by
age 85 (area under the curve 0.76, 95% confidence
interval 0.71 to 0.81; P<0.001). This association
remained for cancers detected more than 20 years
after the blood sample (33 cases, 0.69, P=0.005). Pros-
tate specific antigen was also associated with prostate
cancer metastases (0.86, 0.79 to 0.92; P<0.001), and
Table 2 |Characteristics of 126 (11%) men from study cohort
with diagnosis of prostate cancer. Figures are numbers
(percentages) unless stated otherwise
Data
Clinical T stage:
T1 33 (26)
T2 45 (36)
T3/T4 37 (29)
Unknown 11 (9)
Clinical N stage:
N0 9 (7)
N1 3 (2)
NX 114 (90)
Clinical M stage:
M0 57 (45)
M1 13 (10)
MX 56 (44)
Biopsy grade:
WHO I or Gleason ≤5 29 (23)
WHO II or Gleason 6 or 7 53 (42)
WHO III or Gleason ≥8 20 (16)
Unknown 24 (19)
Median (IQR) PSA at diagnosis (n=86) 17.8 (8.9-38.5)
Age at diagnosis (years):
61-65 15 (12)
66-70 19 (15)
71-75 33 (26)
76-80 27 (21)
81-86 32 (25)
Reason for investigation leading to diagnosis (n=77)*:
Lower urinary tract symptoms* 61 (79)
Haematuria 5 (6)
Erectile dysfunction* 3 (4)
Pain 6 (8)
Metastases (lymph node or bone) 2 (3)
Fatigue 1 (1)
Received treatment for prostate cancer (n=115)†:
Received any treatment 66 (57)
Within six months of diagnosis:
Radical prostatectomy 1 (1)
Medical therapy 32 (28)
Orchidectomy 14 (12)
Radiation therapy 5 (4)
After six months of diagnosis:
Medical treatment 18 (16)
Orchidectomy 6 (5)
Radiation therapy 12 (10)
IQR=interquartile range; PSA=prostate specific antigen.
*1 patient presented with both lower urinary tract symptoms and erectile
dysfunction.
†4 patients received both medical therapy and orchidectomy; 1 patient
had both radiation therapy and orchidectomy; 1 patient had radiation,
medical therapy and orchidectomy.
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P
r
o
p
o
r
t
i
o
n
 
o
f
 
c
a
s
e
s
 
i
d
e
n
t
i
f
i
e
d
100 %
PSA
90
>0.43
80
>0.58
70
>0.72
60
>0.87
50
>1.06
40
>1.31
30
>1.65
20
>2.12
10
>3.40
0
0
20
40
60
80
100
0
11
22
32
43
54
65
76
86
97
108
Identified
Cases per 1000
108
97
86
76
65
54
43
32
22
11
0
Missed
Fig 2 | Lorenz curve for clinically detected prostate cancer: x axis shows percentage of
population with prostate specific antigen (PSA) above indicated concentrations, hence
percentages run from 100 down to 0; y axis shows number of events that would be included
(or missed) if we consider only men with prostate specific antigen above any given
concentration
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P<0.001). Again, these associations remained for
events occurring after 20 years (0.83, P=0.046, in 12
patients with metastasis; 0.84, P=0.051, in 10 patients
who died).
Table 3 gives an initial descriptive analysis of the
association between prostate specific antigen and sub-
sequentprostatecancereventsafterwecategorisedthe
databypopulationquartersofprostatespecificantigen
concentration.Asanexample,menwithaprostatespe-
cificantigenconcentration≥2ng/mlatage60,have,on
average, 26 times the odds of dying from prostate can-
cer than men with a concentration <2 ng/ml. Table 4
gives predicted risks of a diagnosis of prostate cancer,
metastasis, and death by age85 for populationcentiles
of prostate specific antigen; the association is shown
graphically in figure 1, showing strong trends with
increasing concentration. If adjustment is made for
overdiagnosis,
10 the relation between prostate specific
antigen and subsequent clinically detected cancer is
comparablewiththatreportedbetweenprostatespeci-
fic antigen and biopsy detectable cancer in the US
population,
4indicatingbroadapplicabilityofourfind-
ings. The risk of a clinically detected prostate cancer
rises smoothly with increasing concentration of pros-
tate specific antigen; in contrast, metastases and death
from prostate cancer were rare in men with a concen-
trationlessthan1ng/mlatage60,butthenroserapidly
as the concentrations increased. As a result, prostate
specific antigen concentration at age 60 can predict
theprobabilitythatamanwilldiefromprostatecancer
after a subsequent diagnosis. For example, of 25 men
with baseline concentrations of 1-2 ng/ml who were
later diagnosed with prostate cancer, only two (8%)
died from prostate cancer by the end of the study. In
comparison,of18menwithbaselineconcentrationsof
5-10 ng/ml who were later diagnosed with prostate
cancer, six (33%) died from prostate cancer.
Figures 2-4 show Lorenz curves for each event, with
cumulativeprobabilitiesbypopulationcentileshownin
table 5. These results can be used to evaluate risk stra-
tification strategies for screening and early detection. It
can be seen, for example, that 90% of metastases and
95% of deaths occur in men with prostate specific anti-
gen concentrationsabove the median at age 60, equiva-
lent to a concentration of about 1 ng/ml. Men with
concentrations ≤1 ng/ml had a 0.5% probability of
metastasis by age 85 and a 0.2% probability of death
from prostate cancer. Two men in our cohort had con-
centrations close to or less than 1 ng/ml at age 60 and
subsequently died from prostate cancer. These deaths
occurred at age 84 (1.04 ng/ml at baseline) and 85
(0.86 ng/ml at baseline).
Six men in our dataset had prostate specific antigen
concentrations of 20 ng/ml or more, and four of these
mendiedofprostatecancer.Thesemenmighthavehad
incurable disease at the time of the blood sample and
therefore prostate specific antigen based screening at
this age would possibly have made little difference to
their survival. In a sensitivity analysis, we excluded
these six cases but saw no important influence on our
findings:theproportionofdeathsfromcancerinmenin
the top quarter of prostate specific antigen remained at
90%. The proportion of deaths occurring in the top
quarter was also unaffected if we excluded men dying
of prostate cancer within five (91%) or 10 (89%) years.
Baselinefreeprostatespecificantigen,free:totalpros-
tate specific antigen ratio, and hK2 predicted all three
end points. Total prostate specific antigen, however,
was the best single marker, and its predictive accuracy
was enhanced only by the other kallikrein markers for
men with concentrations above the median (table 6).
DISCUSSION
Overview of findings
Concentrations of prostate specific antigen at age 60
predict the risk that a man will die from prostate cancer
by the age of 85. The association between prostate spe-
Table 3 |Conditional logistic regression based on prostate
specific antigen (PSA) concentrations at age 60. Categories
of PSA are close to quarters of distribution
PSA
(ng/ml)
No (%)
of cases
No (%)
of controls
Odds ratio
(95% CI)
Clinically diagnosed prostate cancer
<0.65 9 (7) 101 (27) Reference
0.65-0.99 15 (12) 79 (21) 2.3 (0.89 to 5.7)
1.00-1.99 24 (19) 118 (32) 2.5 (1.1 to 5.9)
≥2.00 77 (62) 75 (20) 13 (5.7 to 29)
Prostate cancer metastases
<0.65 0 (0) 34 (28)
Reference 0.65-0.99 3 (7) 19 (16)
1.00-1.99 5 (12) 36 (30)
≥2.00 34 (81) 32 (26) 17 (5.2 to 57)
Death from prostate cancer
<0.65 0 (0) 25 (26)
Reference 0.65-0.99 1 (3) 15 (15)
1.00-1.99 2 (6) 32 (33)
≥2.00 31 (91) 26 (27) 26 (6.2 to 113)
Proportion of population classified as high risk
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Fig 3 | Lorenz curve for prostate cancer metastasis: x axis shows percentage of population with
prostate specific antigen (PSA) above indicated concentrations, hence percentages run from
100 down to 0; y axis shows number of events that would be included (or missed) if we
consider only men with prostate specific antigen above any given concentration
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than the association between prostate specific antigen
and cancer detectable at biopsy,
4, suggesting that pros-
tate specific antigen concentrations are more useful in
detecting tumours of greater malignant potential.
Our study has several strengths. Participants were
followed to an advanced age, when most had died.
The use of archival anticoagulated plasma has been
shown to reflect prostate specific antigen concentra-
tions had they been measured contemporaneously.
15
Few, if any, men in the cohort would have undergone
prostate specific antigen screening; we therefore
avoided verification bias
22 and were able to provide
estimates for the risk of clinically diagnosed cancer,
rather than biopsy detectable cancer,
4 which might
never affect a man before he dies from another cause.
All men in the study were the same age—one typical
for those currently undergoing screening—ensuring
the direct applicability of our findings. The cohort
was highly representative of the population, and the
large cohort size led to narrow confidence intervals
around most of the risk estimates.
The reason why prostate specific antigen concentra-
tions predicteventsoccurring25years subsequently is
not entirely clear. There are data suggesting that a sig-
nificant proportion of men with concentrations above
themedian,butbelowconventionalbiopsythresholds,
have prostate cancer detectable either by biopsy
7 or
pathological analysis of the prostate at autopsy.
8 Alter-
natively, such increases in prostate specific antigen
might be associated with pre-malignant conditions.
Eitherway,however,theimplicationsarenotobvious.
Even if our findings are driven by detectable prostate
cancers, biopsy would be indicated only if it could be
shown that waiting for the prostate specific antigen
concentration to rise further would result in a substan-
tial risk of the cancer becoming incurable. It is also
unclear whether chemoprevention would be effective
only for pre-malignant states, or whether it might also
have a cytostatic effect on established cancers.
23
Comparison with other studies
Several studies have reported findings that support those
presented here. Stenman and coworkers identified 44
casesofprostatecancerinacohortofover20000Finnish
men and reported associations between baseline prostate
specific antigen and the risk of clinically detected cancer
withinsixto10years.
24Concentrationswerealsofoundto
be raisedfivetosixyearsbefore diagnosisamongthe 366
participantsintheUSPhysicians’HealthStudywhowere
identified with palpable prostate cancer.
25 More recently,
Holmströmandcolleaguesreportedon540casesofpros-
tate cancer in a Swedish cohort, with a comparable find-
ing to ours that prostate specific antigen less than 1 ng/ml
“virtually ruled out prostate cancer” during a mean fol-
low-up of seven years.
26 We have previously reported
datafromtheMalmocohortshowingastrongassociation
between a prostate specific antigen concentration mea-
sured at age 44-50 and prostate cancer diagnosed clini-
cally up to 25 years subsequently
11; the association was
strengthened for cancers that were advanced at
diagnosis.
27 Our current data, however, are unique in
examining the relation of prostate specific antigen con-
centrations at the age appropriate for screening with life-
time risk of metastases or death from prostate cancer.
Clinical implications
Our results have a clear application to early detection
and chemoprevention of prostate cancer. Two rando-
mised trials have recently reported the effects of pros-
tate specific antigen screening on death from prostate
cancer. The Prostate, Lung, Colorectal, and Ovarian
Screeningtrial(PLCO)intheUSdidnotfindanadvan-
tagetoscreeningatamedianfollow-upofsevenyears,
1
althoughimportantconcernshavebeenraisedastothe
widespread use of prostate specific antigen testing in
the control arm of this trial.
28 The European Rando-
mised Trial of Screening for Prostate Cancer
(ERSPC)reporteda20%reductionindeathfrompros-
tate cancer with screening,
2 though it was estimated
that 1410 men needed to be screened to prevent one
death.We found that a highproportionofdeaths from
prostate cancer occur in men with the highest prostate
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Fig 4 | Lorenz curve for death from prostate cancer: x axis shows percentage of population with
prostate specific antigen (PSA) above indicated concentrations, hence percentages run from
100 down to 0; y axis shows number of events that would be included (or missed) if we
consider only men with prostate specific antigen above any given concentration
Table 4 |Risk of clinically diagnosed prostate cancer and death from prostate cancer before
age 85 by prostate specific antigen (PSA) concentration at age 60. Figures are predicted risk
(95% confidence interval)
Centile
PSA
(ng/ml)*
Clinically diagnosed
prostate cancer
Prostate cancer
metastases
Death from prostate
cancer
99 14.8 60 (46 to 73) 32 (21 to 44) 30 (19 to 42)
95 5.17 39 (31 to 47) 19 (12 to 25) 17 (11 to 23)
90 3.40 28 (22 to 33) 12 (8.3 to 16) 11 (7.1 to 15)
80 2.12 17 (14 to 20) 6.6 (4.6 to 8.8) 5.7 (3.8 to 7.7)
75 1.92 15 (13 to 19) 5.8 (4.0 to 7.7) 4.8 (3.2 to 6.6)
67 1.50 11 (8.9 to 14) 3.5 (2.2 to 4.9) 2.7 (1.6 to 3.9)
50 1.06 7.2 (5.4 to 9.1) 1.6 (0.75 to 2.5) 0.9 (0.30 to 1.7)
25 0.65 4.3 (2.4 to 6.4) 0.53 (0.17 to 0.97) 0.28 (0.08 to 0.53)
10 0.43 2.6 (0.91 to 4.9) 0.22 (0.1 to 0.38) 0.14 (0.06 to 0.22)
*Imputed to whole population from case-control data.
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(>3.4 ng/ml) and 95% in men above the median (>1
ng/ml). For men over 60, focusing screening on those
at increased risk—that is, men with concentrations
greater than the median at age 60—is likely to shift
theratioofharmstobenefitsforscreening.Inresponse
toadvocatesofscreeningwhomightcriticiseariskstra-
tification approach as mere cost cutting, we argue that
risk stratification would probably lead to increased
acceptance for screening among patients. Despite sev-
eral recommendations in favour of prostate cancer
screening,
2930 currently only half of age appropriate
US men undergo regular tests.
3 Compliance would
probably increase among those at high risk if they
were informed of their risk status.
Similar considerations apply to chemoprevention.
Targeting treatment to men with increased prostate
specificantigenconcentrationswillreducethemedical
harms and financial costs associated with chemo-
prevention. As for screening, we argue that risk strati-
fication would also increase the benefits of
chemoprevention: despite recommendations,
31 few
men currently undergo chemoprevention for prostate
cancer.
32 This could change if a subgroup of men were
told that they were at high risk of clinically relevant
prostate cancer.
With regard to counselling of individual patients, it
has been suggested that the prostate specific antigen
test is insufficiently sensitive for prostate cancer on
the grounds that a substantial proportion of men with
low concentrations have prostate cancer on biopsy.
47
In contrast, our findings suggest that 60 year old men
with low concentrations can be reassured that even if
theydoharbourcancer,itisunlikelytobecomeappar-
entduringtheirlifetimeandevenlesslikelytobecome
life threatening.
None the less,a raisedprostatespecific antigen isfar
from being an inevitable harbinger of advanced pros-
tate cancer. For instance, only one in six men at the
95th centile of prostate specific antigen at age 60 (5.2
ng/ml) will die of prostate cancer by age 85. Hence,
while a concentration below the median (≤1 ng/ml)
canprobably“ruleout”subsequentdeathormetastasis
from prostate cancer, higher concentrations indicate
only that careful monitoring might be warranted.
Limitations
Our findings are subject to several important caveats.
Firstly, our data are based on a single blood test in
60 year old men without screening. This means that,
for men undergoing screening in their 50s, we prob-
ably overestimate the risk of a clinical diagnosis of
prostate cancer after the age of 60. This is because
some men would have been diagnosed early with can-
cerdetectedatscreeningandthusberemovedfromthe
risk set. That said, a small decrease in risk has little
effect for most men because most are at low risk, and
therearenopracticalimplicationstomisclassifications
betweendifferentlevelsofreducedrisk.Moreover,itis
prudent to be conservative with respect to risk. We
might have also overestimated the risk of clinically
detected prostate cancer because overdetection can
occur even in the absence of screening. For example,
amanpresentingtoaurologistwithprostatesymptoms
might have a cancer detected during the clinical inves-
tigation that would never have become apparent had
the patient not developed concurrent benign disease.
Neither of these considerations would have an
important effect on our estimates of death from pros-
tatecancer.Suchestimatesmight,however,beaffected
by improvements in treatment, such as the use of
higher dose radiotherapy. Even so, under the assump-
tion of an approximately constant relative reduction
from improved treatment, changes in treatment are
unlikely to have an important effect on estimates of
cumulative proportions, such as that 90% of prostate
cancer deaths occur in men in the top quarter of pros-
tate specific antigen concentrations at age 60.
Table 6 |Association between prostate cancer outcomes and total prostate specific antigen
(PSA), free PSA, % free PSA, and kallikrein related peptidase 2 (hK2) at age 60, overall and
for men with total PSA above median. Figures are areas under curve (95% CI); the greater the
value the better the test
Clinically diagnosed
prostate cancer
Prostate cancer
metastases
Death from prostate
cancer
All men aged 60
No of cases/controls 125/373 42/121 34/98
Model:
Total PSA 0.76 (0.71 to 0.81) 0.86 (0.79 to 0.93) 0.90 (0.84 to 0.96)
Free PSA 0.74 (0.69 to 0.80) 0.83 (0.77 to 0.91) 0.88 (0.81 to 0.95)
% free PSA 0.70 (0.65 to 0.75) 0.78 (0.70 to 0.86) 0.80 (0.71 to 0.88)
hK2 0.69 (0.64 to 0.75) 0.77 (0.64 to 0.86) 0.81 (0.72 to 0.90)
Combination* 0.76 (0.71 to 0.81) 0.87 (0.81 to 0.93) 0.91 (0.86 to 0.97)
Men aged 60 with PSA ≥ ≥1.0 ng/ml (median)
No of cases/controls 101/193 39/68 33/58
Model:
Total PSA 0.75 (0.69 to 0.81) 0.82 (0.73 to 0.91) 0.85 (0.77 to 0.94)
Free PSA 0.73 (0.67 to 0.79) 0.79 (0.70 to 0.88) 0.83 (0.74 to 0.92)
% free PSA 0.65 (0.58 to 0.71) 0.73 (0.63 to 0.83) 0.76 (0.65 to 0.86)
hK2 0.68 (0.62 to 0.75) 0.75 (0.64 to 0.85) 0.77 (0.66 to 0.88)
Combination* 0.74 (0.68 to 0.81) 0.85 (0.76 to 0.92) 0.89 (0.83 to 0.96)
*Total PSA, free PSA, % free PSA, and hK2.
Table 5 |Cumulative proportion (%) of cases (95% confidence
intervals) above centiles of prostate specific antigen (PSA)
concentration
Centile
PSA
(ng/ml)*
Prostate
cancers
Prostate cancer
metastases
Prostate
cancer
deaths
90 3.40 41(33 to50) 61 (46 to 77) 66 (49 to 83)
80 2.12 58(50 to66) 76 (61 to 89) 85 (71 to 97)
75 1.92 62(54 to70) 80 (68 to 93) 90 (78 to >99)
67 1.50 70(61 to78) 84 (72 to 95) 91 (79 to >99)
50 1.06 80(72 to87) 91 (81 to >99) 95 (86 to >99)
25 0.65 93(88 to97) 99 (94 to >99) >99(97to>99)
10 0.43 99(95to>99) >99 (—) >99 (—)
*Imputed to whole population from case-control data.
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Several questions remain for future research. One is
whether these results can be replicated in an indepen-
dent group. Secondly, it is unclear how well our risk
estimates apply to men of other races. Both incidence
of and mortality from prostate cancer are higher in
African-Americans and lower in Asians than in white
people.
33 Whether there are also racial differences in
the relation between prostate specific antigen at age
60 and future risks of prostate cancer metastases and
deathisaquestionthatcanbeansweredonlybyfurther
research.
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